{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:53:30Z","timestamp":1791359610091,"version":"4.3.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Central nervous system (CNS) tumours are the deadliest cancer for children and currently present limited treatment options. Chimeric antigen receptor (CAR)-T cell therapies have emerged as an innovative approach supported by encouraging clinical results. Current clinical trials using CAR-T cells in the treatment of paediatric CNS cancers differ in a number of variables, including the CAR-T cell route of delivery, presence of lymphodepletion, identified target antigen, and CAR engineering features. Considering early learnings across these areas is an essential step to developing more effective treatment options, especially given the challenges of immunosuppressive tumour microenvironments, various toxicities, CAR-T cell exhaustion, and tumour antigen heterogeneity. In sum, while there is a need for continued innovation, CAR-T cells represent a promising treatment approach for this devastating category of diseases.<\/jats:p>","DOI":"10.1007\/s11060-026-05604-5","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:34:44Z","timestamp":1787913284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T cell therapy: potential for paediatric brain tumours\u2014an update"],"prefix":"10.1007","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-7723","authenticated-orcid":false,"given":"Alexandra","family":"Zehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7735-3988","authenticated-orcid":false,"given":"Benjamin","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-9807","authenticated-orcid":false,"given":"Darren","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-5539","authenticated-orcid":false,"given":"Laura K.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-3203","authenticated-orcid":false,"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"5604_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ncl.2018.04.009","volume":"36","author":"YT Udaka","year":"2018","unstructured":"Udaka YT, Packer RJ (2018) Pediatric Brain Tumors. Neurol Clin 36:533\u2013556. https:\/\/doi.org\/10.1016\/j.ncl.2018.04.009","journal-title":"Neurol Clin"},{"key":"5604_CR2","unstructured":"Curtin SC, Minino AM, Anderson RN (2016) Declines in Cancer Death Rates Among Children and Adolescents in the United States, 1999\u20132014. NCHS Data Brief 1\u20138"},{"key":"5604_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","volume":"24","author":"ML Persson","year":"2022","unstructured":"Persson ML, Douglas AM, Alvaro F et al (2022) The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. Neurooncology 24:1408\u20131422. https:\/\/doi.org\/10.1093\/neuonc\/noac117","journal-title":"Neurooncology"},{"key":"5604_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.it.2019.05.009","volume":"40","author":"SS Wang","year":"2019","unstructured":"Wang SS, Bandopadhayay P, Jenkins MR (2019) Towards Immunotherapy for Pediatric Brain Tumors. Trends Immunol 40:748\u2013761. https:\/\/doi.org\/10.1016\/j.it.2019.05.009","journal-title":"Trends Immunol"},{"key":"5604_CR5","doi-asserted-by":"publisher","first-page":"vdab027","DOI":"10.1093\/noajnl\/vdab027","volume":"3","author":"HE Olsen","year":"2021","unstructured":"Olsen HE, Lynn GM, Valdes PA et al (2021) Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. Neuro-Oncology Adv 3:vdab027. https:\/\/doi.org\/10.1093\/noajnl\/vdab027","journal-title":"Neuro-Oncology Adv"},{"key":"5604_CR6","first-page":"4048","volume":"61","author":"S Modak","year":"2001","unstructured":"Modak S, Kramer K, Gultekin SH et al (2001) Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61:4048\u20134054","journal-title":"Cancer Res"},{"key":"5604_CR7","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.adcanc.2022.100035","volume":"4","author":"U Ahmad","year":"2022","unstructured":"Ahmad U, Khan Z, Ualiyeva D et al (2022) Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Adv Cancer Biology - Metastasis 4:100035. https:\/\/doi.org\/10.1016\/j.adcanc.2022.100035","journal-title":"Adv Cancer Biology - Metastasis"},{"key":"5604_CR8","doi-asserted-by":"publisher","unstructured":"Feins S, Kong W, Williams EF et al (2019) An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol 94. https:\/\/doi.org\/10.1002\/ajh.25418","DOI":"10.1002\/ajh.25418"},{"key":"5604_CR9","doi-asserted-by":"publisher","first-page":"e20230903","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM et al (2024) CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med 221:e20230903. https:\/\/doi.org\/10.1084\/jem.20230903","journal-title":"J Exp Med"},{"key":"5604_CR10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D et al (2024) Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 30:1001\u20131012. https:\/\/doi.org\/10.1038\/s41591-024-02875-1","journal-title":"Nat Med"},{"key":"5604_CR11","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R et al (2016) Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med 375:2561\u20132569. https:\/\/doi.org\/10.1056\/NEJMoa1610497","journal-title":"N Engl J Med"},{"key":"5604_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4963","author":"LA Johnson","year":"2015","unstructured":"Johnson LA, Scholler J, Ohkuri T et al (2015) Rational development and characterization of humanized anti\u2013EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4963. 7:","journal-title":"Sci Transl Med"},{"key":"5604_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","volume":"26","author":"LK Donovan","year":"2020","unstructured":"Donovan LK, Delaidelli A, Joseph SK et al (2020) Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med 26:720\u2013731. https:\/\/doi.org\/10.1038\/s41591-020-0827-2","journal-title":"Nat Med"},{"key":"5604_CR14","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I et al (2023) GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med 388:1284\u20131295. https:\/\/doi.org\/10.1056\/NEJMoa2210859","journal-title":"N Engl J Med"},{"key":"5604_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M et al (2017) HER2-Specific Chimeric Antigen Receptor\u2013Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol 3:1094. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0184","journal-title":"JAMA Oncol"},{"key":"5604_CR16","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza NA, Johnson AJ, Wilson AL et al (2021) Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med 27:1544\u20131552. https:\/\/doi.org\/10.1038\/s41591-021-01404-8","journal-title":"Nat Med"},{"key":"5604_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R et al (2025) Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637:708\u2013715. https:\/\/doi.org\/10.1038\/s41586-024-08171-9","journal-title":"Nature"},{"key":"5604_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M et al (2025) Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med 31:861\u2013868. https:\/\/doi.org\/10.1038\/s41591-024-03451-3","journal-title":"Nat Med"},{"key":"5604_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","volume":"17","author":"H Kadry","year":"2020","unstructured":"Kadry H, Noorani B, Cucullo L (2020) A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17:69. https:\/\/doi.org\/10.1186\/s12987-020-00230-3","journal-title":"Fluids Barriers CNS"},{"key":"5604_CR20","first-page":"58","volume":"29","author":"PB Medawar","year":"1948","unstructured":"Medawar PB (1948) Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58\u201369","journal-title":"Br J Exp Pathol"},{"key":"5604_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1084\/jem.38.2.183","volume":"38","author":"JB Murphy","year":"1923","unstructured":"Murphy JB, Sturm E, CONDITIONS DETERMINING THE TRANSPLANTABILITY OF TISSUES IN THE BRAIN (1923) J Exp Med 38:183\u2013197. https:\/\/doi.org\/10.1084\/jem.38.2.183","journal-title":"J Exp Med"},{"key":"5604_CR22","doi-asserted-by":"publisher","first-page":"618427","DOI":"10.3389\/fimmu.2020.618427","volume":"11","author":"KJ Caldwell","year":"2021","unstructured":"Caldwell KJ, Gottschalk S, Talleur AC (2021) Allogeneic CAR Cell Therapy\u2014More Than a Pipe Dream. Front Immunol 11:618427. https:\/\/doi.org\/10.3389\/fimmu.2020.618427","journal-title":"Front Immunol"},{"key":"5604_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson JH, Gunn MD, Fecci PE, Ashley DM (2020) Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20:12\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0224-7","journal-title":"Nat Rev Cancer"},{"key":"5604_CR24","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1172\/JCI41911","volume":"120","author":"EH Wilson","year":"2010","unstructured":"Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Invest 120:1368\u20131379. https:\/\/doi.org\/10.1172\/JCI41911","journal-title":"J Clin Invest"},{"key":"5604_CR25","doi-asserted-by":"publisher","first-page":"1142597","DOI":"10.3389\/fimmu.2023.1142597","volume":"14","author":"G Del Baldo","year":"2023","unstructured":"Del Baldo G, Del Bufalo F, Pinacchio C et al (2023) The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors. Front Immunol 14:1142597. https:\/\/doi.org\/10.3389\/fimmu.2023.1142597","journal-title":"Front Immunol"},{"key":"5604_CR26","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1084\/jem.20070064","volume":"204","author":"I Galea","year":"2007","unstructured":"Galea I, Bernardes-Silva M, Forse PA et al (2007) An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med 204:2023\u20132030. https:\/\/doi.org\/10.1084\/jem.20070064","journal-title":"J Exp Med"},{"key":"5604_CR27","doi-asserted-by":"publisher","first-page":"805657","DOI":"10.3389\/fimmu.2022.805657","volume":"13","author":"JA Mapunda","year":"2022","unstructured":"Mapunda JA, Tibar H, Regragui W, Engelhardt B (2022) How Does the Immune System Enter the Brain? Front Immunol 13:805657. https:\/\/doi.org\/10.3389\/fimmu.2022.805657","journal-title":"Front Immunol"},{"key":"5604_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12974-016-0763-8","volume":"13","author":"D Lobo-Silva","year":"2016","unstructured":"Lobo-Silva D, Carriche GM, Castro AG et al (2016) Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation 13:297. https:\/\/doi.org\/10.1186\/s12974-016-0763-8","journal-title":"J Neuroinflammation"},{"key":"5604_CR29","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D (2019) Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant 25:e123\u2013e127. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756","journal-title":"Biol Blood Marrow Transplant"},{"key":"5604_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","journal-title":"Nat Rev Immunol"},{"key":"5604_CR31","doi-asserted-by":"publisher","first-page":"1206983","DOI":"10.3389\/fonc.2023.1206983","volume":"13","author":"L Gatto","year":"2023","unstructured":"Gatto L, Ricciotti I, Tosoni A et al (2023) CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap. Front Oncol 13:1206983. https:\/\/doi.org\/10.3389\/fonc.2023.1206983","journal-title":"Front Oncol"},{"key":"5604_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K et al (2023) Tumor inflammation-associated neurotoxicity. Nat Med 29:803\u2013810. https:\/\/doi.org\/10.1038\/s41591-023-02276-w","journal-title":"Nat Med"},{"key":"5604_CR33","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","volume":"188","author":"AC Geraghty","year":"2025","unstructured":"Geraghty AC, Acosta-Alvarez L, Rotiroti MC et al (2025) Immunotherapy-related cognitive impairment after CAR T cell therapy in mice. Cell 188:3238\u20133258e25. https:\/\/doi.org\/10.1016\/j.cell.2025.03.041","journal-title":"Cell"},{"key":"5604_CR34","doi-asserted-by":"publisher","unstructured":"Hines MR, Knight TE, McNerney KO et al (2023) Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplantation Cell Therapy 29. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006.:438.e1-438.e16","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"5604_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/archneur.64.2.185","volume":"64","author":"O Aktas","year":"2007","unstructured":"Aktas O, Ullrich O, Infante-Duarte C et al (2007) Neuronal Damage in Brain Inflammation. Arch Neurol 64:185. https:\/\/doi.org\/10.1001\/archneur.64.2.185","journal-title":"Arch Neurol"},{"key":"5604_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","volume":"13","author":"X Gu","year":"2024","unstructured":"Gu X, Zhang Y, Zhou W et al (2024) Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. Exp Hematol Oncol 13:70. https:\/\/doi.org\/10.1186\/s40164-024-00542-2","journal-title":"Exp Hematol Oncol"},{"key":"5604_CR37","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, Zhao Y, Levine BL et al (2017) Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunol Res 5:1152\u20131161. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0189","journal-title":"Cancer Immunol Res"},{"key":"5604_CR38","doi-asserted-by":"publisher","first-page":"e007162","DOI":"10.1136\/jitc-2023-007162","volume":"11","author":"S Papa","year":"2023","unstructured":"Papa S, Adami A, Metoudi M et al (2023) Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J Immunother Cancer 11:e007162. https:\/\/doi.org\/10.1136\/jitc-2023-007162","journal-title":"J Immunother Cancer"},{"key":"5604_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhou J, Yang X et al (2023) Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer 22:3. https:\/\/doi.org\/10.1186\/s12943-022-01711-9","journal-title":"Mol Cancer"},{"key":"5604_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","volume":"24","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Tilakawardane D, Jeang B et al (2018) Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2\u2009+\u2009Breast Cancer Metastasis to the Brain. Clin Cancer Res 24:95\u2013105. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2041","journal-title":"Clin Cancer Res"},{"key":"5604_CR41","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath J, Sotillo E, Mount CW et al (2020) Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat Med 26:712\u2013719. https:\/\/doi.org\/10.1038\/s41591-020-0821-8","journal-title":"Nat Med"},{"key":"5604_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown CE, Aguilar B, Starr R et al (2018) Optimization of IL13R\u03b12-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Mol Ther 26:31\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.002","journal-title":"Mol Ther"},{"key":"5604_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","volume":"21","author":"SA Rosenberg","year":"2009","unstructured":"Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233\u2013240. https:\/\/doi.org\/10.1016\/j.coi.2009.03.002","journal-title":"Curr Opin Immunol"},{"key":"5604_CR44","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clin Cancer Res 17:4550\u20134557. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116","journal-title":"Clin Cancer Res"},{"key":"5604_CR45","doi-asserted-by":"publisher","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V et al (2023) Lymphodepletion \u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 14:1303935. https:\/\/doi.org\/10.3389\/fimmu.2023.1303935","journal-title":"Front Immunol"},{"key":"5604_CR46","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","volume":"31","author":"F Locatelli","year":"2025","unstructured":"Locatelli F, Pagliara D, De Ioris MA et al (2025) GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial. Nat Med 31:3689\u20133699. https:\/\/doi.org\/10.1038\/s41591-025-03874-6","journal-title":"Nat Med"},{"key":"5604_CR47","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/1078-0432.CCR-24-3083","volume":"31","author":"S Mehta","year":"2025","unstructured":"Mehta S, Ippagunta S, Varadharajan S et al (2025) B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response. Clin Cancer Res 31:3754\u20133770. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3083","journal-title":"Clin Cancer Res"},{"key":"5604_CR48","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha B, Inal C, Owonikoko TK (2020) Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol 10:1000. https:\/\/doi.org\/10.3389\/fonc.2020.01000","journal-title":"Front Oncol"},{"key":"5604_CR49","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.3.5.909","author":"G Lammie","year":"1993","unstructured":"Lammie G, Cheung N, Gerald W et al (1993) GANGLIOSIDE GD(2) EXPRESSION IN THE HUMAN NERVOUS-SYSTEM AND IN NEUROBLASTOMAS - AN IMMUNOHISTOCHEMICAL STUDY. Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.3.5.909","journal-title":"Int J Oncol"},{"key":"5604_CR50","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. N Engl J Med 363:1324\u20131334. https:\/\/doi.org\/10.1056\/NEJMoa0911123","journal-title":"N Engl J Med"},{"key":"5604_CR51","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-015-0399-5","volume":"75","author":"S Dhillon","year":"2015","unstructured":"Dhillon S (2015) Dinutuximab: First Global Approval. Drugs 75:923\u2013927. https:\/\/doi.org\/10.1007\/s40265-015-0399-5","journal-title":"Drugs"},{"key":"5604_CR52","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor\u2013positive T cells in patients with neuroblastoma. Blood 118:6050\u20136056. https:\/\/doi.org\/10.1182\/blood-2011-05-354449","journal-title":"Blood"},{"key":"5604_CR53","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount CW, Majzner RG, Sundaresh S et al (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med 24:572\u2013579. https:\/\/doi.org\/10.1038\/s41591-018-0006-x","journal-title":"Nat Med"},{"key":"5604_CR54","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603:934\u2013941. https:\/\/doi.org\/10.1038\/s41586-022-04489-4","journal-title":"Nature"},{"key":"5604_CR55","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","volume":"30","author":"R Ciccone","year":"2024","unstructured":"Ciccone R, Quintarelli C, Camera A et al (2024) GD2-Targeting CAR T-cell Therapy for Patients with GD2\u2009+\u2009Medulloblastoma. Clin Cancer Res 30:2545\u20132557. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1880","journal-title":"Clin Cancer Res"},{"key":"5604_CR56","doi-asserted-by":"publisher","first-page":"eabd6169","DOI":"10.1126\/scitranslmed.abd6169","volume":"12","author":"K Straathof","year":"2020","unstructured":"Straathof K, Flutter B, Wallace R et al (2020) Antitumor activity without on-target off-tumor toxicity of GD2\u2013chimeric antigen receptor T cells in patients with neuroblastoma. Sci Transl Med 12:eabd6169. https:\/\/doi.org\/10.1126\/scitranslmed.abd6169","journal-title":"Sci Transl Med"},{"key":"5604_CR57","doi-asserted-by":"publisher","first-page":"701006","DOI":"10.3389\/fimmu.2021.701006","volume":"12","author":"W-T Zhou","year":"2021","unstructured":"Zhou W-T, Jin W-L (2021) B7-H3\/CD276: An Emerging Cancer Immunotherapy. Front Immunol 12:701006. https:\/\/doi.org\/10.3389\/fimmu.2021.701006","journal-title":"Front Immunol"},{"key":"5604_CR58","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","volume":"23","author":"D Haydar","year":"2021","unstructured":"Haydar D, Houke H, Chiang J et al (2021) Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neurooncology 23:999\u20131011. https:\/\/doi.org\/10.1093\/neuonc\/noaa278","journal-title":"Neurooncology"},{"key":"5604_CR59","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A et al (2019) CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res 25:2560\u20132574. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432","journal-title":"Clin Cancer Res"},{"key":"5604_CR60","doi-asserted-by":"publisher","first-page":"O8","DOI":"10.1186\/2051-1426-3-S2-O8","volume":"3","author":"J Powderly","year":"2015","unstructured":"Powderly J, Cote G, Flaherty K et al (2015) Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer 3:O8. https:\/\/doi.org\/10.1186\/2051-1426-3-S2-O8","journal-title":"J Immunother Cancer"},{"key":"5604_CR61","doi-asserted-by":"publisher","first-page":"100160","DOI":"10.1016\/j.ejcped.2024.100160","volume":"3","author":"R Epperly","year":"2024","unstructured":"Epperly R, Gottschalk S, DeRenzo C (2024) CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives. EJC Pediatr Oncol 3:100160. https:\/\/doi.org\/10.1016\/j.ejcped.2024.100160","journal-title":"EJC Pediatr Oncol"},{"key":"5604_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","volume":"47","author":"D Nehama","year":"2019","unstructured":"Nehama D, Di Ianni N, Musio S et al (2019) B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine 47:33\u201343. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.030","journal-title":"EBioMedicine"},{"key":"5604_CR63","doi-asserted-by":"publisher","first-page":"188802","DOI":"10.1016\/j.bbcan.2022.188802","volume":"1877","author":"M Ja\u00e9n","year":"2022","unstructured":"Ja\u00e9n M, Mart\u00edn-Regalado \u00c1, Bartolom\u00e9 RA et al (2022) Interleukin 13 receptor alpha 2 (IL13R\u03b12): Expression, signaling pathways and therapeutic applications in cancer. Biochimica et Biophysica Acta (BBA) -. Reviews Cancer 1877:188802. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188802","journal-title":"Reviews Cancer"},{"key":"5604_CR64","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1158\/1078-0432.CCR-21-0361","volume":"27","author":"RA M\u00e1rquez-Ortiz","year":"2021","unstructured":"M\u00e1rquez-Ortiz RA, Contreras-Z\u00e1rate MJ, Tesic V et al (2021) IL13R\u03b12 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases. Clin Cancer Res 27:6209\u20136221. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0361","journal-title":"Clin Cancer Res"},{"key":"5604_CR65","doi-asserted-by":"publisher","first-page":"32902","DOI":"10.18632\/oncotarget.5361","volume":"6","author":"M Xie","year":"2015","unstructured":"Xie M, Wu X, Zhang J, He C (2015) IL-13 receptor \u03b12 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice. Oncotarget 6:32902\u201332913. https:\/\/doi.org\/10.18632\/oncotarget.5361","journal-title":"Oncotarget"},{"key":"5604_CR66","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/cncr.22134","volume":"107","author":"M Kioi","year":"2006","unstructured":"Kioi M, Kawakami M, Shimamura T et al (2006) Interleukin-13 receptor \u03b12 chain: A potential biomarker and molecular target for ovarian cancer therapy. Cancer 107:1407\u20131418. https:\/\/doi.org\/10.1002\/cncr.22134","journal-title":"Cancer"},{"key":"5604_CR67","doi-asserted-by":"publisher","first-page":"8678","DOI":"10.1158\/0008-5472.CAN-09-2100","volume":"69","author":"T Fujisawa","year":"2009","unstructured":"Fujisawa T, Joshi B, Nakajima A, Puri RK (2009) A Novel Role of Interleukin-13 Receptor \u03b12 in Pancreatic Cancer Invasion and Metastasis. Cancer Res 69:8678\u20138685. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2100","journal-title":"Cancer Res"},{"key":"5604_CR68","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41598-019-39018-3","volume":"9","author":"H Okamoto","year":"2019","unstructured":"Okamoto H, Yoshimatsu Y, Tomizawa T et al (2019) Interleukin-13 receptor \u03b12 is a novel marker and potential therapeutic target for human melanoma. Sci Rep 9:1281. https:\/\/doi.org\/10.1038\/s41598-019-39018-3","journal-title":"Sci Rep"},{"key":"5604_CR69","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/0008-5472.CAN-11-4090","volume":"72","author":"R Barderas","year":"2012","unstructured":"Barderas R, Bartolom\u00e9 RA, Fernandez-Ace\u00f1ero MJ et al (2012) High Expression of IL-13 Receptor \u03b12 in Colorectal Cancer Is Associated with Invasion, Liver Metastasis, and Poor Prognosis. Cancer Res 72:2780\u20132790. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-4090","journal-title":"Cancer Res"},{"key":"5604_CR70","first-page":"985","volume":"5","author":"W Debinski","year":"1999","unstructured":"Debinski W, Gibo DM, Hulet SW et al (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5:985\u2013990","journal-title":"Clin Cancer Res"},{"key":"5604_CR71","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-11-1669","volume":"18","author":"CE Brown","year":"2012","unstructured":"Brown CE, Starr R, Aguilar B et al (2012) Stem-like Tumor-Initiating Cells Isolated from IL13R\u03b12 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine\u2013Redirected T Cells. Clin Cancer Res 18:2199\u20132209. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1669","journal-title":"Clin Cancer Res"},{"key":"5604_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biology Int 2014:1\u20139. https:\/\/doi.org\/10.1155\/2014\/852748","journal-title":"Mol Biology Int"},{"key":"5604_CR73","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. JCO 17:2639\u20132639. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2639","journal-title":"JCO"},{"key":"5604_CR74","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-007-9424-1","volume":"85","author":"J-F Mineo","year":"2007","unstructured":"Mineo J-F, Bordron A, Baroncini M et al (2007) Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 85:281\u2013287. https:\/\/doi.org\/10.1007\/s11060-007-9424-1","journal-title":"J Neurooncol"},{"key":"5604_CR75","doi-asserted-by":"publisher","first-page":"vdad024","DOI":"10.1093\/noajnl\/vdad024","volume":"5","author":"SS Wang","year":"2023","unstructured":"Wang SS, Davenport AJ, Iliopoulos M et al (2023) HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma. Neuro-Oncology Adv 5:vdad024. https:\/\/doi.org\/10.1093\/noajnl\/vdad024","journal-title":"Neuro-Oncology Adv"},{"key":"5604_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/1092587","volume":"2019","author":"A Rutkowska","year":"2019","unstructured":"Rutkowska A, Stoczy\u0144ska-Fidelus E, Janik K et al (2019) EGFRvIII: An Oncogene with Ambiguous Role. J Oncol 2019:1\u201320. https:\/\/doi.org\/10.1155\/2019\/1092587","journal-title":"J Oncol"},{"key":"5604_CR77","first-page":"2164","volume":"51","author":"AJ Ekstrand","year":"1991","unstructured":"Ekstrand AJ, James CD, Cavenee WK et al (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164\u20132172","journal-title":"Cancer Res"},{"key":"5604_CR78","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","volume":"23","author":"J Felsberg","year":"2017","unstructured":"Felsberg J, Hentschel B, Kaulich K et al (2017) Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR -Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. Clin Cancer Res 23:6846\u20136855. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0890","journal-title":"Clin Cancer Res"},{"key":"5604_CR79","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.1158\/1078-0432.CCR-08-3210","volume":"15","author":"DA Bax","year":"2009","unstructured":"Bax DA, Gaspar N, Little SE et al (2009) EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines. Clin Cancer Res 15:5753\u20135761. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3210","journal-title":"Clin Cancer Res"},{"key":"5604_CR80","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1111\/febs.12393","volume":"280","author":"HK Gan","year":"2013","unstructured":"Gan HK, Cvrljevic AN, Johns TG (2013) The epidermal growth factor receptor variant III (EGFR v III): where wild things are altered. FEBS J 280:5350\u20135370. https:\/\/doi.org\/10.1111\/febs.12393","journal-title":"FEBS J"},{"key":"5604_CR81","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/neuonc\/noab231","volume":"24","author":"Y Hoogstrate","year":"2022","unstructured":"Hoogstrate Y, Ghisai SA, De Wit M et al (2022) The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. Neurooncology 24:429\u2013441. https:\/\/doi.org\/10.1093\/neuonc\/noab231","journal-title":"Neurooncology"},{"key":"5604_CR82","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Binder ZA, Lamrani L et al (2024) Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer 5:517\u2013531. https:\/\/doi.org\/10.1038\/s43018-023-00709-6","journal-title":"Nat Cancer"},{"key":"5604_CR83","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.18632\/oncotarget.27389","volume":"10","author":"AC Ravanpay","year":"2019","unstructured":"Ravanpay AC, Gust J, Johnson AJ et al (2019) EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget 10:7080\u20137095. https:\/\/doi.org\/10.18632\/oncotarget.27389","journal-title":"Oncotarget"},{"key":"5604_CR84","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, Yang X, Ye S et al (2024) Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies. Biomed Pharmacother 178:117252. https:\/\/doi.org\/10.1016\/j.biopha.2024.117252","journal-title":"Biomed Pharmacother"},{"key":"5604_CR85","doi-asserted-by":"publisher","unstructured":"Papadimitriou M, Ahn S, Diamond B et al (2024) Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies. https:\/\/doi.org\/10.1101\/2024.05.22.595383. bioRxiv 2024.05.22.595383","DOI":"10.1101\/2024.05.22.595383"},{"key":"5604_CR86","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, Han W (2019) Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol 12:128. https:\/\/doi.org\/10.1186\/s13045-019-0813-7","journal-title":"J Hematol Oncol"},{"key":"5604_CR87","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA et al (2024) Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med 30:1320\u20131329. https:\/\/doi.org\/10.1038\/s41591-024-02893-z","journal-title":"Nat Med"},{"key":"5604_CR88","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.ymthe.2023.03.020","volume":"31","author":"E Kokalaki","year":"2023","unstructured":"Kokalaki E, Ma B, Ferrari M et al (2023) Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. Mol Ther 31:2089\u20132104. https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.020","journal-title":"Mol Ther"},{"key":"5604_CR89","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13046-023-02838-3","volume":"42","author":"A Timpanaro","year":"2023","unstructured":"Timpanaro A, Piccand C, Dzhumashev D et al (2023) CD276-CAR T cells and Dual-CAR T cells targeting CD276\/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models. J Exp Clin Cancer Res 42:293. https:\/\/doi.org\/10.1186\/s13046-023-02838-3","journal-title":"J Exp Clin Cancer Res"},{"key":"5604_CR90","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian S, Lucchini G, Richardson R et al (2024) CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood 143:118\u2013123. https:\/\/doi.org\/10.1182\/blood.2023020621","journal-title":"Blood"},{"key":"5604_CR91","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/cac2.12474","volume":"43","author":"Z Wang","year":"2023","unstructured":"Wang Z, Lu Y, Liu Y et al (2023) Novel CD123\u00d7CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single\u2010target CAR\u2010T with no more hematotoxicity. Cancer Commun 43:1178\u20131182. https:\/\/doi.org\/10.1002\/cac2.12474","journal-title":"Cancer Commun"},{"key":"5604_CR92","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1038\/s41467-024-50251-x","volume":"15","author":"M Tian","year":"2024","unstructured":"Tian M, Wei JS, Cheuk AT-C et al (2024) CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma. Nat Commun 15:6222. https:\/\/doi.org\/10.1038\/s41467-024-50251-x","journal-title":"Nat Commun"},{"key":"5604_CR93","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li N, Rodriguez JL, Yin Y et al (2024) Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma. Mol Ther 32:3522\u20133538. https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.020","journal-title":"Mol Ther"},{"key":"5604_CR94","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T et al (2013) TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Therapy - Nucleic Acids 2:e105. https:\/\/doi.org\/10.1038\/mtna.2013.32","journal-title":"Mol Therapy - Nucleic Acids"},{"key":"5604_CR95","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1089\/104303401753153947","volume":"12","author":"M Kumar","year":"2001","unstructured":"Kumar M, Keller B, Makalou N, Sutton RE (2001) Systematic Determination of the Packaging Limit of Lentiviral Vectors. Hum Gene Ther 12:1893\u20131905. https:\/\/doi.org\/10.1089\/104303401753153947","journal-title":"Hum Gene Ther"},{"key":"5604_CR96","doi-asserted-by":"publisher","first-page":"10437","DOI":"10.1073\/pnas.95.18.10437","volume":"95","author":"T Clackson","year":"1998","unstructured":"Clackson T, Yang W, Rozamus LW et al (1998) Redesigning an FKBP\u2013ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 95:10437\u201310442. https:\/\/doi.org\/10.1073\/pnas.95.18.10437","journal-title":"Proc Natl Acad Sci USA"},{"key":"5604_CR97","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P et al (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood 105:4247\u20134254. https:\/\/doi.org\/10.1182\/blood-2004-11-4564","journal-title":"Blood"},{"key":"5604_CR98","doi-asserted-by":"publisher","first-page":"100457","DOI":"10.1016\/j.xcrm.2021.100457","volume":"2","author":"T Muliaditan","year":"2021","unstructured":"Muliaditan T, Halim L, Whilding LM et al (2021) Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. Cell Rep Med 2:100457. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100457","journal-title":"Cell Rep Med"},{"key":"5604_CR99","doi-asserted-by":"publisher","first-page":"836549","DOI":"10.3389\/fimmu.2022.836549","volume":"13","author":"L Halim","year":"2022","unstructured":"Halim L, Das KK, Larcombe-Young D et al (2022) Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation. Front Immunol 13:836549. https:\/\/doi.org\/10.3389\/fimmu.2022.836549","journal-title":"Front Immunol"},{"key":"5604_CR100","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y et al (2021) Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer 2:904\u2013918. https:\/\/doi.org\/10.1038\/s43018-021-00244-2","journal-title":"Nat Cancer"},{"key":"5604_CR101","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner S, Mansilla-Soto J, Nataraj S et al (2023) Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41:1871\u20131891e6. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.010","journal-title":"Cancer Cell"},{"key":"5604_CR102","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1006\/jmbi.2000.4265","volume":"305","author":"A W\u00f6rn","year":"2001","unstructured":"W\u00f6rn A, Pl\u00fcckthun A (2001) Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305:989\u20131010. https:\/\/doi.org\/10.1006\/jmbi.2000.4265","journal-title":"J Mol Biol"},{"key":"5604_CR103","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","volume":"26","author":"W Xiong","year":"2018","unstructured":"Xiong W, Chen Y, Kang X et al (2018) Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther 26:963\u2013975. https:\/\/doi.org\/10.1016\/j.ymthe.2018.01.020","journal-title":"Mol Ther"},{"key":"5604_CR104","doi-asserted-by":"publisher","unstructured":"Tong C, Zhang Y, Liu Y et al (2020) Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B cell lymphoma. Blood blood 2020005278. https:\/\/doi.org\/10.1182\/blood.2020005278","DOI":"10.1182\/blood.2020005278"},{"key":"5604_CR105","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","volume":"12","author":"JH Cho","year":"2021","unstructured":"Cho JH, Okuma A, Sofjan K et al (2021) Engineering advanced logic and distributed computing in human CAR immune cells. Nat Commun 12:792. https:\/\/doi.org\/10.1038\/s41467-021-21078-7","journal-title":"Nat Commun"},{"key":"5604_CR106","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1093\/neuonc\/noaf115","volume":"27","author":"JB Foster","year":"2025","unstructured":"Foster JB, Madsen PJ, Harvey K et al (2025) Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models. Neurooncology 27:2684\u20132696. https:\/\/doi.org\/10.1093\/neuonc\/noaf115","journal-title":"Neurooncology"},{"key":"5604_CR107","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q et al (2022) Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics 12:6273\u20136290. https:\/\/doi.org\/10.7150\/thno.76854","journal-title":"Theranostics"},{"key":"5604_CR108","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3389\/fonc.2020.01117","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, Wu H, Chen G et al (2020) Arming Anti-EGFRvIII CAR-T With TGF\u03b2 Trap Improves Antitumor Efficacy in Glioma Mouse Models. Front Oncol 10:1117. https:\/\/doi.org\/10.3389\/fonc.2020.01117","journal-title":"Front Oncol"},{"key":"5604_CR109","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung I-Y et al (2022) PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28:724\u2013734. https:\/\/doi.org\/10.1038\/s41591-022-01726-1","journal-title":"Nat Med"},{"key":"5604_CR110","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/cells12091316","volume":"12","author":"B Ko","year":"2023","unstructured":"Ko B, Takebe N, Andrews O et al (2023) Rethinking Oncologic Treatment Strategies with Interleukin-2. Cells 12:1316. https:\/\/doi.org\/10.3390\/cells12091316","journal-title":"Cells"},{"key":"5604_CR111","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","volume":"135","author":"MT Lotze","year":"1985","unstructured":"Lotze MT, Matory YL, Ettinghausen SE et al (1985) In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865\u20132875","journal-title":"J Immunol"},{"key":"5604_CR112","doi-asserted-by":"publisher","first-page":"1005582","DOI":"10.3389\/fimmu.2022.1005582","volume":"13","author":"J Kremer","year":"2022","unstructured":"Kremer J, Henschel P, Simon D et al (2022) Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors. Front Immunol 13:1005582. https:\/\/doi.org\/10.3389\/fimmu.2022.1005582","journal-title":"Front Immunol"},{"key":"5604_CR113","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A et al (2025) Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637:940\u2013946. https:\/\/doi.org\/10.1038\/s41586-024-08261-8","journal-title":"Nature"},{"key":"5604_CR114","doi-asserted-by":"publisher","first-page":"295","DOI":"10.14740\/jh1367","volume":"13","author":"K Hickmann","year":"2024","unstructured":"Hickmann K, DiLeo R, Faringer K et al (2024) A Case of Fulminant Cerebral Edema Leading to Death After Chimeric Antigen Receptor T-Cell Therapy. J Hematol 13:295\u2013299. https:\/\/doi.org\/10.14740\/jh1367","journal-title":"J Hematol"},{"key":"5604_CR115","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/jnen\/nlaa099","volume":"79","author":"DF Marker","year":"2020","unstructured":"Marker DF, Kofler JK, Mettenburg JA et al (2020) Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature. J Neuropathology Experimental Neurol 79:1115\u20131121. https:\/\/doi.org\/10.1093\/jnen\/nlaa099","journal-title":"J Neuropathology Experimental Neurol"},{"key":"5604_CR116","doi-asserted-by":"publisher","first-page":"1124198","DOI":"10.3389\/fonc.2023.1124198","volume":"13","author":"M Mantica","year":"2023","unstructured":"Mantica M, Drappatz J (2023) Immunotherapy associated central nervous system complications in primary brain tumors. Front Oncol 13:1124198. https:\/\/doi.org\/10.3389\/fonc.2023.1124198","journal-title":"Front Oncol"},{"key":"5604_CR117","doi-asserted-by":"publisher","first-page":"eads3403","DOI":"10.1126\/sciadv.ads3403","volume":"11","author":"KC Vogt","year":"2025","unstructured":"Vogt KC, Silberman PC, Lin Q et al (2025) Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Sci Adv 11:eads3403. https:\/\/doi.org\/10.1126\/sciadv.ads3403","journal-title":"Sci Adv"},{"key":"5604_CR118","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS et al (2021) SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med 13:eabe7378. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378","journal-title":"Sci Transl Med"},{"key":"5604_CR119","doi-asserted-by":"publisher","first-page":"eadl4237","DOI":"10.1126\/science.adl4237","volume":"386","author":"MS Simic","year":"2024","unstructured":"Simic MS, Watchmaker PB, Gupta S et al (2024) Programming tissue-sensing T cells that deliver therapies to the brain. Science 386:eadl4237. https:\/\/doi.org\/10.1126\/science.adl4237","journal-title":"Science"},{"key":"5604_CR120","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.ymthe.2021.05.006","volume":"29","author":"B Webster","year":"2021","unstructured":"Webster B, Xiong Y, Hu P et al (2021) Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19\u2009+\u2009Raji lymphoma in preclinical models. Mol Ther 29:2691\u20132706. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.006","journal-title":"Mol Ther"},{"key":"5604_CR121","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann K, Giavridis T, Weber J et al (2019) The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med 11:eaau5907. https:\/\/doi.org\/10.1126\/scitranslmed.aau5907","journal-title":"Sci Transl Med"},{"key":"5604_CR122","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.chembiol.2020.11.012","volume":"28","author":"S Carbonneau","year":"2021","unstructured":"Carbonneau S, Sharma S, Peng L et al (2021) An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell Chem Biology 28:802\u2013812e6. https:\/\/doi.org\/10.1016\/j.chembiol.2020.11.012","journal-title":"Cell Chem Biology"},{"key":"5604_CR123","doi-asserted-by":"publisher","unstructured":"Harvey K, Madsen PJ, Smith T et al (2023) Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice. JoVE 64886. https:\/\/doi.org\/10.3791\/64886","DOI":"10.3791\/64886"},{"key":"5604_CR124","doi-asserted-by":"publisher","unstructured":"Oluwole OO, Ray MD, Ma H et al (2025) Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed\/Refractory Large B-cell Lymphoma: A US Cost-Effectiveness Analysis. Transplantation and Cellular Therapy S2666636725011662. https:\/\/doi.org\/10.1016\/j.jtct.2025.05.002","DOI":"10.1016\/j.jtct.2025.05.002"},{"key":"5604_CR125","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/CJI.0000000000000413","volume":"45","author":"A Michaux","year":"2022","unstructured":"Michaux A, Mau\u00ebn S, Breman E et al (2022) Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non\u2013Gene-edited Allogeneic CAR T-Cell Therapy. J Immunother 45:150\u2013161. https:\/\/doi.org\/10.1097\/CJI.0000000000000413","journal-title":"J Immunother"},{"key":"5604_CR126","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1158\/2326-6066.CIR-23-1001","volume":"12","author":"PY Teo","year":"2024","unstructured":"Teo PY, Jung Y, Quach DH et al (2024) Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy. Cancer Immunol Res 12:1108\u20131122. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-1001","journal-title":"Cancer Immunol Res"},{"key":"5604_CR127","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11864-023-01061-8","volume":"24","author":"Y An","year":"2023","unstructured":"An Y, Jin X, Zhang H et al (2023) Off-the-Shelf Allogeneic CAR Cell Therapy\u2014Neglected HvG Effect. Curr Treat Options Oncol 24:409\u2013441. https:\/\/doi.org\/10.1007\/s11864-023-01061-8","journal-title":"Curr Treat Options Oncol"},{"key":"5604_CR128","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/cup.14601","volume":"51","author":"A Nihal","year":"2024","unstructured":"Nihal A, Comstock JR, Bennett DD et al (2024) Histopathologic evidence of chimeric antigen receptor T- cell therapy in lesions of B\u2010cell lymphoblastic leukemia cutis. J Cutan Pathol 51:562\u2013564. https:\/\/doi.org\/10.1111\/cup.14601","journal-title":"J Cutan Pathol"},{"key":"5604_CR129","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T et al (2024) Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. N Engl J Med 390:2047\u20132060. https:\/\/doi.org\/10.1056\/NEJMoa2401361","journal-title":"N Engl J Med"},{"key":"5604_CR130","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","volume":"31","author":"JK Jadlowsky","year":"2025","unstructured":"Jadlowsky JK, Hexner EO, Marshall A et al (2025) Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med 31:1134\u20131144. https:\/\/doi.org\/10.1038\/s41591-024-03478-6","journal-title":"Nat Med"},{"key":"5604_CR131","doi-asserted-by":"publisher","first-page":"13685","DOI":"10.3390\/ijms252413685","volume":"25","author":"L Gehrke","year":"2024","unstructured":"Gehrke L, Gon\u00e7alves VDR, Andrae D et al (2024) Current Non-Viral-Based Strategies to Manufacture CAR-T Cells. IJMS 25:13685. https:\/\/doi.org\/10.3390\/ijms252413685","journal-title":"IJMS"},{"key":"5604_CR132","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Harrison EB, Li H et al (2022) Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat Commun 13:2154. https:\/\/doi.org\/10.1038\/s41467-022-29647-0","journal-title":"Nat Commun"},{"key":"5604_CR133","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A et al (2019) CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun 10:4016. https:\/\/doi.org\/10.1038\/s41467-019-11869-4","journal-title":"Nat Commun"},{"key":"5604_CR134","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1038\/s41467-025-64861-6","volume":"16","author":"EZ Song","year":"2025","unstructured":"Song EZ, Timpanaro A, Meechan M et al (2025) Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma. Nat Commun 16:9914. https:\/\/doi.org\/10.1038\/s41467-025-64861-6","journal-title":"Nat Commun"},{"key":"5604_CR135","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-024-01635-5","volume":"17","author":"X Li","year":"2024","unstructured":"Li X, Wang X, Wang H et al (2024) A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy. J Hematol Oncol 17:116. https:\/\/doi.org\/10.1186\/s13045-024-01635-5","journal-title":"J Hematol Oncol"},{"key":"5604_CR136","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1021\/acsnano.3c10109","volume":"18","author":"C Tang","year":"2024","unstructured":"Tang C, Jing W, Han K et al (2024) mRNA-Laden Lipid-Nanoparticle-Enabled in Situ CAR-Macrophage Engineering for the Eradication of Multidrug-Resistant Bacteria in a Sepsis Mouse Model. ACS Nano 18:2261\u20132278. https:\/\/doi.org\/10.1021\/acsnano.3c10109","journal-title":"ACS Nano"},{"key":"5604_CR137","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K et al (2025) Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405:127\u2013136. https:\/\/doi.org\/10.1016\/S0140-6736(24)02462-0","journal-title":"Lancet"},{"key":"5604_CR138","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/neuonc\/noaa047","volume":"22","author":"S Khatua","year":"2020","unstructured":"Khatua S, Cooper LJN, Sandberg DI et al (2020) Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neurooncology 22:1214\u20131225. https:\/\/doi.org\/10.1093\/neuonc\/noaa047","journal-title":"Neurooncology"},{"key":"5604_CR139","doi-asserted-by":"publisher","first-page":"1145706","DOI":"10.3389\/fimmu.2023.1145706","volume":"14","author":"P Zuo","year":"2023","unstructured":"Zuo P, Li Y, He C et al (2023) Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas. Front Immunol 14:1145706. https:\/\/doi.org\/10.3389\/fimmu.2023.1145706","journal-title":"Front Immunol"},{"key":"5604_CR140","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00262-024-03808-0","volume":"73","author":"T Tachi","year":"2024","unstructured":"Tachi T, Kijima N, Kuroda H et al (2024) Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Cancer Immunol Immunother 73:256. https:\/\/doi.org\/10.1007\/s00262-024-03808-0","journal-title":"Cancer Immunol Immunother"},{"key":"5604_CR141","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/neuonc\/nop056","volume":"12","author":"L Yu","year":"2010","unstructured":"Yu L, Baxter PA, Voicu H et al (2010) A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neurooncology 12:580\u2013594. https:\/\/doi.org\/10.1093\/neuonc\/nop056","journal-title":"Neurooncology"},{"key":"5604_CR142","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1634\/stemcells.2007-1009","volume":"26","author":"Q Shu","year":"2008","unstructured":"Shu Q, Wong KK, Su JM et al (2008) Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133\u2009+\u2009Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma. Stem Cells 26:1414\u20131424. https:\/\/doi.org\/10.1634\/stemcells.2007-1009","journal-title":"Stem Cells"},{"key":"5604_CR143","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ame2.12399","volume":"8","author":"J Gao","year":"2025","unstructured":"Gao J, Zhao Y, Wang Z et al (2025) Single-cell transcriptomic sequencing identifies subcutaneous patient\u2010derived xenograft recapitulated medulloblastoma. Anim Models Exp Med 8:458\u2013472. https:\/\/doi.org\/10.1002\/ame2.12399","journal-title":"Anim Models Exp Med"},{"key":"5604_CR144","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ccell.2014.11.002","volume":"27","author":"RM Hill","year":"2015","unstructured":"Hill RM, Kuijper S, Lindsey JC et al (2015) Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell 27:72\u201384. https:\/\/doi.org\/10.1016\/j.ccell.2014.11.002","journal-title":"Cancer Cell"},{"key":"5604_CR145","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/cells10030712","volume":"10","author":"WH Hicks","year":"2021","unstructured":"Hicks WH, Bird CE, Traylor JI et al (2021) Contemporary Mouse Models in Glioma Research. Cells 10:712. https:\/\/doi.org\/10.3390\/cells10030712","journal-title":"Cells"},{"key":"5604_CR146","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nature09173","volume":"466","author":"RA Johnson","year":"2010","unstructured":"Johnson RA, Wright KD, Poppleton H et al (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466:632\u2013636. https:\/\/doi.org\/10.1038\/nature09173","journal-title":"Nature"},{"key":"5604_CR147","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1158\/2159-8290.CD-23-0004","volume":"13","author":"M McNicholas","year":"2023","unstructured":"McNicholas M, De Cola A, Bashardanesh Z et al (2023) A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities. Cancer Discov 13:1592\u20131615. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0004","journal-title":"Cancer Discov"},{"key":"5604_CR148","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/neuonc\/noab182","volume":"24","author":"P Chuntova","year":"2022","unstructured":"Chuntova P, Hou Y, Naka R et al (2022) Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. Neurooncology 24:259\u2013272. https:\/\/doi.org\/10.1093\/neuonc\/noab182","journal-title":"Neurooncology"},{"key":"5604_CR149","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/CJI.0b013e3182187600","volume":"34","author":"SP Kerkar","year":"2011","unstructured":"Kerkar SP, Sanchez-Perez L, Yang S et al (2011) Genetic Engineering of Murine CD8\u2009+\u2009and CD4\u2009+\u2009T Cells for Preclinical Adoptive Immunotherapy Studies. J Immunother 34:343\u2013352. https:\/\/doi.org\/10.1097\/CJI.0b013e3182187600","journal-title":"J Immunother"},{"key":"5604_CR150","doi-asserted-by":"publisher","first-page":"102898","DOI":"10.1016\/j.xpro.2024.102898","volume":"5","author":"D Zhang","year":"2024","unstructured":"Zhang D, Krimitza E, Han K et al (2024) Protocol to generate traceable CAR T cells for syngeneic mouse cancer models. STAR Protocols 5:102898. https:\/\/doi.org\/10.1016\/j.xpro.2024.102898","journal-title":"STAR Protocols"},{"key":"5604_CR151","doi-asserted-by":"publisher","first-page":"e1107","DOI":"10.1002\/cpz1.1107","volume":"4","author":"M Hosseini","year":"2024","unstructured":"Hosseini M, Akbari B, Shahverdi AR et al (2024) Generation of Murine Chimeric Antigen Receptor-Modified T Cells for In Vivo Studies in Syngeneic Tumor Models. Curr Protocols 4:e1107. https:\/\/doi.org\/10.1002\/cpz1.1107","journal-title":"Curr Protocols"},{"key":"5604_CR152","doi-asserted-by":"publisher","first-page":"102234","DOI":"10.1016\/j.xpro.2023.102234","volume":"4","author":"A Heller","year":"2023","unstructured":"Heller A, Du F, Liu Y et al (2023) Generating a mouse model for relapsed Sonic Hedgehog medulloblastoma. STAR Protocols 4:102234. https:\/\/doi.org\/10.1016\/j.xpro.2023.102234","journal-title":"STAR Protocols"},{"key":"5604_CR153","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-22-2108","volume":"82","author":"A Borgenvik","year":"2022","unstructured":"Borgenvik A, Holmberg KO, Bolin S et al (2022) Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma. Cancer Res 82:4586\u20134603. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2108","journal-title":"Cancer Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05604-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05604-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05604-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:34:48Z","timestamp":1791358488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05604-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":153,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5604"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05604-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"62"}}